

ScopeSys Welcomes Padma Kodukula as Chief Executive Officer and James Taylor as Chairman of the Board

Life-science analytics company accelerates transition from technology validation to scale-up and commercial growth

Vancouver, BC – [November 25, 2025] – ScopeSys Inc., an innovator in single-molecule imaging and analytics for genomic medicines, today announced the appointment of Padma Kodukula, PhD, MBA, as Chief Executive Officer and James Taylor, PhD, as Chairman of the Board. These leadership appointments mark an important milestone as the company advances from market validation of its technology platform to building a scalable, global business.

ScopeSys' proprietary Convex Lens-induced Confinement (CLiC) platform enables multi-parametric, quantitative analysis of nanoparticle delivery systems, nucleic acid payloads and real-time visualization of their entry and trafficking within live cells. Developed in the Leslie Lab at the University of British Columbia, the platform has now been validated in multiple peer-reviewed publications and industry partnerships, demonstrating its power to link biophysical characteristics to drug performance.

"Bringing Padma and James on board is a pivotal step in ScopeSys' journey," said Sabrina Leslie, PhD, Co-Founder, Chief Scientific Officer, and President of ScopeSys. "Over the past several years, we have advanced CLiC from an academic prototype to a robust platform. Now we're poised to translate it into benchtop instruments and analytical services that will empower drug developers worldwide. Padma's track record building and scaling life-science platforms, and James' experience creating high-value organizations, provide the ideal leadership to guide our next chapter."

Dr. Kodukula has over 25 years of experience across platform development, business development, and commercialization in leading life-science companies, including A-Alpha Bio, Precision NanoSystems, Thermo Fisher Scientific, and BD Biosciences. Working at the intersection of science and business, she has executed partnerships with big pharma, secured non-dilutive funding and equity financing, and built teams and businesses that created incremental company value.

"The ability to directly visualize and quantify nanoparticle size, payload, and behavior in real-time is highly valuable to drug developers and critical for manufacturing controls," said Padma Kodukula, CEO of ScopeSys. "I'm thrilled to join the company at this inflection point to scale our technology into accessible, high-impact solutions that help the design, development and manufacturing of genomic medicines faster and with greater success."

James Taylor, a serial entrepreneur and industry veteran who co-founded and led Precision NanoSystems through significant growth and successful acquisition, brings

decades of expertise in guiding life-science tool companies from early innovation to commercial scale.

“ScopeSys’ CLiC platform fills a critical gap in how we characterize, understand and optimize next-generation genomic medicines,” said James Taylor, Chairman of the Board. “Sabrina’s scientific breakthroughs have laid a strong foundation. With Padma’s leadership, ScopeSys is ready to bring this transformative platform to researchers and industry partners worldwide. I’m excited to help accelerate this business transition to scale-up and commercialization.”

ScopeSys is currently expanding its team, advancing its ScopeTop™ instrument and associated analytical services, and engaging with pharmaceutical and biotech companies working on nanoparticle formulations, oligo-based medicines, and additional advanced drug delivery systems.

About ScopeSys

ScopeSys is a life-science analytics company with a mission to advance the next generation of genomic medicines. Our proprietary Convex Lens-induced Confinement (CLiC) platform delivers single-molecule, multi-parametric, quantitative measurements of molecules, nanoparticles, and cells for measuring critical drug characteristics from discovery through manufacturing. Translating our technology into benchtop instruments, consumables, and analytical services, ScopeSys enables drug developers with data and insights to design better therapies, faster. The company is headquartered in Vancouver, BC.